Delivery Order SPE2DR25D3201-SPE2DR26FT6DN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,553.06 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count) with an ultimate completion date of December 9, 2025. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive award criteria. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency (DLA) awarded a $19,458.59 delivery order to AmerisourceBergen Drug Corp on January 16, 2026, for the supply of Ondansetron ODT 4 mg tablets (30-count packages). The contract represents a firm fixed-price delivery order with an ultimate completion date of January 20, 2026, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made on a competitive basis with no set-aside designation. AmerisourceBergen Drug Corp, a subsidiary...
- The Defense Logistics Agency awarded a delivery order valued at $6,348.74 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of August 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procedures. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count) valued at $11,571.36 under a firm fixed-price contract. The award was made on November 14, 2025, with an ultimate completion date of November 17, 2025. This non-competitive delivery order represents a routine pharmaceutical procurement to support federal medical supply needs, with performance to occur at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $20,798.10 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. The contract is a firm fixed price delivery order with no set-aside designation, competitively awarded on September 9, 2025, with an ultimate completion date of September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this transaction. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,140.42 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This competitively awarded, firm fixed-price delivery order was executed on November 13, 2025, with an ultimate completion date of November 14, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. No...
- The Defense Logistics Agency awarded a delivery order valued at $7,137.20 to Amerisourcebergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) on January 12, 2026, with an ultimate completion date of January 13, 2026. This firm fixed-price delivery order was awarded on a non-set-aside, competitive basis and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,607.95 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply). This was a competitively awarded, firm fixed-price delivery order with no set-aside designation, completed on December 16, 2025, with an ultimate completion date of December 17, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $18,470.50 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $2,295.50 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This competitively awarded, firm fixed-price delivery order was issued on January 16, 2026, with an ultimate completion date of January 20, 2026. The pharmaceutical product will be performed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under the parent entity...
- SPE2DR25D3201Indefinite Delivery Contract
- SPE2DR25D3201-SPE2DR26FT6DNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,348.60 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This firm fixed-price delivery order, issued on January 30, 2026, with an ultimate completion date of February 2, 2026, represents a routine pharmaceutical procurement executed through open competition with no set-aside designation. The contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent company, Cencora, Inc., holds the primary IDC with DLA valued up to $999,999,999.00 through December 31, 2031, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen's extensive federal contract portfolio demonstrates its role as a critical supplier of prescription medications, generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 1/29/26 |